Outline of patents

Clarification of Previously Announced Press Release: SoLVBL Solutions Inc. Announces Update on the Second Provisional Patent Application

Retrieved on: 
Tuesday, March 9, 2021
Intellectual property law, United States patent law, Intangible assets, International Searching and Preliminary Examining Authorities, Patent offices, Provisional application, Patent, United States Patent and Trademark Office, Trademark, Term of patent in the United States, Outline of patents

Provisional Patent Application" (the "Original Press Release").

Key Points: 
  • Provisional Patent Application" (the "Original Press Release").
  • Due to recent queries regarding the Original Press Release, the following press release provides additional information and clarification on certain statements regarding filing of the Second U.S.
  • Provisional Patent Application with the United States Patent and Trademark Office (the "Second U.S.
  • In the Original Press Release, the Company set out the parameters of the Second U.S.

Canntab Granted 3rd Patent and Receives $400K Purchase Order in Australia

Retrieved on: 
Tuesday, March 9, 2021
Patent law, Patent, Outline of patents

The Company now has patent protection in the USA, Canada and Australia providing an international scope to the Company's expanding portfolio of issued patents."

Key Points: 
  • The Company now has patent protection in the USA, Canada and Australia providing an international scope to the Company's expanding portfolio of issued patents."
  • Canntab has eleven pending patent applications internationally and three patents which have now been granted.
  • Canntab has developed both patented and patent pending technologies to deliver standardized medical cannabis extract in a variety of extended-release/ sustained-release pharmaceutical grade delivery systems.
  • Canntab is also pleased to announce that further to an announcement made on October 26, 2020, Canntab has now received an initial purchase order in the amount of $406,200 with its Australian partner, Cann Global Limited of Australia ("Cann Global").

Anixa Biosciences Announces European Patent Issued for its CAR-T Cancer Therapy

Retrieved on: 
Thursday, March 4, 2021
Intellectual property law, Countries, Law, European Patent Organisation, Patent law, Business law, Monopoly, Patent, European Patent Office, Inventor, European Patent Convention, Outline of patents

The patent is titled, "METHODS AND COMPOSITIONS FOR TREATING CANCER," and the inventors are Drs.

Key Points: 
  • The patent is titled, "METHODS AND COMPOSITIONS FOR TREATING CANCER," and the inventors are Drs.
  • The patent is assigned to The Wistar Institute and Anixa Biosciences' majority-owned subsidiary, Certainty Therapeutics, Inc., which is the exclusive, world-wide licensee.
  • Dr. Amit Kumar, President and CEO of Anixa Biosciences, stated, "We are pleased that the European Patent Office (EPO) has issued this patent.
  • This patent will provide protection of our technology throughout the European Union, in addition to the existing protection from our issued patent in the United States.

Tricida Granted Additional U.S. Patent Covering Composition of Matter of Veverimer

Retrieved on: 
Wednesday, March 3, 2021
Patent law, Patent, Creativity, Outline of patents, Business law, Thought, Double patenting

The newly issued patent covers additional composition of matter claims for veverimer to 2038 and extends the Tricida patent portfolio, which is solely owned by the company, to a total of 210 patents in 49 different countries, including two previously issued U.S. composition of matter patents and four issued U.S. method of treatment patents which provide protection to 2034.

Key Points: 
  • The newly issued patent covers additional composition of matter claims for veverimer to 2038 and extends the Tricida patent portfolio, which is solely owned by the company, to a total of 210 patents in 49 different countries, including two previously issued U.S. composition of matter patents and four issued U.S. method of treatment patents which provide protection to 2034.
  • Tricida solely owns other patent applications relating to veverimer that are currently pending in Australia, Brazil, Canada, China, Europe, Hong Kong, India, Israel, Japan, Mexico, Republic of Korea, Russia, and the United States.
  • This new composition of matter patent will enable us to fully capitalize on veverimers U.S. potential into 2038, said Gerrit Klaerner, Ph.D., Tricidas Chief Executive Officer and President.
  • This patent adds four years of additional patent protection to our timeline to obtain the full value of veverimer.

DGAP-News: Virpax(R) Pharmaceuticals Inc.: Virpax Pharmaceuticals Announces Newly Issued Patent for Probudur(TM)

Retrieved on: 
Tuesday, March 2, 2021
Intellectual property law, Monopoly, Patent law, Intellectual property organizations, Patent, United States patent law, United States Patent and Trademark Office, Pharmaceutical industry in China, Outline of patents

WEST CHESTER, PA, March 2, 2021 - Virpax(R) Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced that the United States Patent and Trademark Office issued US Patent No.

Key Points: 
  • WEST CHESTER, PA, March 2, 2021 - Virpax(R) Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced that the United States Patent and Trademark Office issued US Patent No.
  • This newly issued patent, which is owned by LipoCure Rx and exclusively licensed to Virpax, has 18 claims and expires in 2029.
  • "We are extremely pleased with the continued development of the patent portfolio for ProbudurTM, our long-acting anesthetic for postoperative pain management.
  • This newly issued patent further broadens our overall intellectual property portfolio," stated Anthony Mack, Chairman and CEO of Virpax.

Pointivo Lands Eighth Patent Increasing Coverage of the Drone Analytics Market

Retrieved on: 
Tuesday, February 23, 2021
Patent law, Monopoly, Patent, Creativity, Outline of patents, Property law, Business law

Once issued, Pointivo will own eight US patents, with several other US and foreign patent applications pending.

Key Points: 
  • Once issued, Pointivo will own eight US patents, with several other US and foreign patent applications pending.
  • This patent covers the ability to automatically generate engineering CAD drawings from imagery captured from drones and other devices.
  • New Pointivo patent covers ability to automatically generate engineering CAD drawings from imagery captured from drones.
  • Pointivo is a pioneer in the use of AI and computer vision to extract information from imagery derived from various capture methods.

Croatia grants Lleida.net a patent for its method of receiving certified emails

Retrieved on: 
Tuesday, February 23, 2021
Patent offices, Intangible assets, Intellectual property law, International Searching and Preliminary Examining Authorities, SIPO, Patent, China National Intellectual Property Administration, State Intellectual Property Office, Intellectual property, Trademark, Outline of patents

This patent, granted in Zagreb by theCroatianState Intellectual Property Office (SIPO), is valid for 20 years.

Key Points: 
  • This patent, granted in Zagreb by theCroatianState Intellectual Property Office (SIPO), is valid for 20 years.
  • The grant follows a patent granted for this method by the European Patent and Trademark Office in 2019.
  • It is also the method used by the Spanish FootballLeague for its audiovisual rights auction.
  • Lleida.net, which has more than 3,000 shareholders, is listed on BME Growth in Madrid, the OTCQX index in New York and Euronext Growth in Paris.

Croatia grants Lleida.net a patent for its method of receiving certified emails

Retrieved on: 
Tuesday, February 23, 2021
Patent offices, Intangible assets, Intellectual property law, International Searching and Preliminary Examining Authorities, SIPO, Patent, China National Intellectual Property Administration, State Intellectual Property Office, Intellectual property, Trademark, Outline of patents

This patent, granted in Zagreb by theCroatianState Intellectual Property Office (SIPO), is valid for 20 years.

Key Points: 
  • This patent, granted in Zagreb by theCroatianState Intellectual Property Office (SIPO), is valid for 20 years.
  • The grant follows a patent granted for this method by the European Patent and Trademark Office in 2019.
  • It is also the method used by the Spanish FootballLeague for its audiovisual rights auction.
  • Lleida.net, which has more than 3,000 shareholders, is listed on BME Growth in Madrid, the OTCQX index in New York and Euronext Growth in Paris.

GTT Group Releases 4th Quarter Patent Transaction Market Report (PTMR)

Retrieved on: 
Tuesday, February 16, 2021
Monopoly, Intangible assets, Patent, Patent law, Outline of patents

PORTLAND, Ore., Feb. 16, 2021 /PRNewswire-PRWeb/ -- Global Technology Transfer Group, Inc. (GTT Group), a world leader in strategic patent analysis and patent transaction services, today makes available the Fourth Quarter 2020 Patent Transaction Market Report (PTMR) including the Patent Market Index (PMI) and the Patent Licensing Index (PLI) results.

Key Points: 
  • PORTLAND, Ore., Feb. 16, 2021 /PRNewswire-PRWeb/ -- Global Technology Transfer Group, Inc. (GTT Group), a world leader in strategic patent analysis and patent transaction services, today makes available the Fourth Quarter 2020 Patent Transaction Market Report (PTMR) including the Patent Market Index (PMI) and the Patent Licensing Index (PLI) results.
  • For more than a decade, GTT Group's Patent Transaction Market Report has been providing subscribers key data on the health of the patent marketplace.
  • Within the Patent Transaction Market Report, you will find the industry's benchmark indexes and forecasting that are essential to understanding the current market and planning for the future.
  • The Patent Market Index (PMI) tracks patent transaction activity and is reported quarterly in the Patent Transaction Market Report (PTMR).

Palatin Technologies Announces Filing of International Patent Application Claiming PL9643

Retrieved on: 
Wednesday, February 10, 2021
Countries, Government, Foreign relations, Patent law, Term of patent in the United States, Term of patent, Patent application, Patent, Priority right, Outline of patents, European Patent Convention

Palatin recently reported positive results in its Phase 2 study of PL9643 for the treatment of Dry Eye Disease (DED).

Key Points: 
  • Palatin recently reported positive results in its Phase 2 study of PL9643 for the treatment of Dry Eye Disease (DED).
  • A Phase 2/3 clinical trial with PL9643 for the treatment of DED is currently planned for mid-2021.
  • The PCT application for PL9643 establishes the base for the presumptive patent term, and if a patent is granted which claims priority to this application, could provide patent protection for PL9643, and any product in which PL9643 is the active pharmaceutical ingredient, out to 2041, excluding any additional term for patent adjustment or patent term extension.
  • We anticipate filing patent applications in the United States, Europe and a number of additional regions and countries throughout the world.